Summary

UK Vaccines Market
The UK vaccines market was valued at $1.4 billion in 2023 and is projected to reach $3.0 billion by 2033, growing at a CAGR of 7.7% from 2024 to 2033.
A vaccine is a biological substance administered to protect individuals against infectious and potentially life-threatening diseases. It contains either the whole or a specific component of viruses, bacteria, or toxins responsible for diseases. Vaccines work by stimulating the immune system to trigger a defense against these pathogens without causing the disease. Key components of a vaccine include antigens, adjuvants, stabilizers, and preservatives. There are various types of vaccines, each designed to stimulate the immune system in different ways, such as inactivated vaccines, subunit vaccines, live attenuated vaccines, toxoid vaccines, and DNA or mRNA vaccines.

Increase in public health campaigns and free immunization initiatives by the National Health Service is a key driver of the UK vaccines market. In addition, rise in awareness among individuals regarding the importance of vaccination, particularly after the COVID-19 pandemic, has propelled the development of the market. A notable trend gaining prominence in the market in recent times is the formation of compound vaccines. These vaccines comprise varying antigens from bacteria, viruses, and other microorganisms, resulting in the development of one formulation offering protection against multiple diseases.
However, the extensive approval process established by the UK Medicines and Healthcare products Regulatory Agency for the commercialization of new vaccines hampers the development of the market. Furthermore, rise in the prevalence of disease variants due to frequent mutations in microorganisms restrains the market growth significantly. On the contrary, rise in the inclination of medical facilities and government in the UK toward developing vaccines for chronic diseases is projected to present remunerative opportunities for the market. For instance, The BMJ—a British publisher of medical journals—states that the UK is poised to become a hotbed of cancer vaccine trials as around 30 British hospitals have signed up to be part of the Cancer Vaccine Launch Pad in 2024.

Segment Review
The UK vaccines market is segmented into technology type, indication, and end user. On the basis of technology type, the market is divided into inactivated vaccines, toxoid vaccines, recombinant & conjugate vaccines, live attenuated vaccines, and others. As per indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, & rubella; diphtheria, pertussis, & tetanus (DTP); polio; hepatitis; and other indications. By end user, it is categorized into pediatric, adults, and travelers.
Key Findings
On the basis of technology type, the recombinant & conjugate vaccines segment was the highest shareholder in 2023.
Depending on indication, the human papilloma virus segment held a notable share of the market in 2023.
As per end user, the pediatric segment dominated the market in 2023.
Competition Analysis
The major players in the global UK vaccines market include Pfizer, Valneva SE, Viatris Inc., AstraZeneca, Emergex Vaccines, Sanofi, Bavarian Nordic A/S, Prokarium, Merck & Co., Inc., and GSK plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology Type
● Inactivated Vaccines
● Toxoid Vaccines
● Recombinant and Conjugate Vaccines
● Live Attenuated Vaccines
● Others
By Indication
● Pneumococcal Disease
● Influenza
● Human Papilloma Virus
● Meningococcal Disease
● Rotavirus
● Varicella
● Measles, Mumps, and Rubella
● Diphtheria, Pertussis, and Tetanus (DTP)
● Polio
● Hepatitis
● Other Indications
By End User
● Pediatric
● Adults
● Travelers
● Key Market Players
○ Pfizer
○ Valneva SE
○ Viatris Inc.
○ AstraZeneca
○ Emergex Vaccines
○ Sanofi
○ Bavarian Nordic A/S
○ Prokarium
○ Merck & Co., Inc.
○ GSK plc.

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: UK VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology Type
4.2. Inactivated Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.3. Toxoid Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.4. Recombinant And Conjugate Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.5. Live Attenuated Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 5: UK VACCINES MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Pneumococcal Disease
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.3. Influenza
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.4. Human Papilloma Virus
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.5. Meningococcal Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.6. Rotavirus
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.7. Varicella
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.8. Measles, Mumps, And Rubella
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.9. Diphtheria, Pertussis, And Tetanus (DTP)
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.10. Polio
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.11. Hepatitis
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.12. Other Indications
5.12.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 6: UK VACCINES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Pediatric
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.3. Adults
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.4. Travelers
6.4.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning,2023
CHAPTER 8: COMPANY PROFILES
8.1. Pfizer
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Valneva SE
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Viatris Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. AstraZeneca
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Emergex Vaccines
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Sanofi
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Bavarian Nordic A/S
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Prokarium
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Merck And Co., Inc.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. GSK Plc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. UK VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 3. UK VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 4. PFIZER: KEY EXECUTIVES
TABLE 5. PFIZER: COMPANY SNAPSHOT
TABLE 6. PFIZER: OPERATING SEGMENTS
TABLE 7. PFIZER: PRODUCT PORTFOLIO
TABLE 8. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 9. VALNEVA SE: KEY EXECUTIVES
TABLE 10. VALNEVA SE: COMPANY SNAPSHOT
TABLE 11. VALNEVA SE: OPERATING SEGMENTS
TABLE 12. VALNEVA SE: PRODUCT PORTFOLIO
TABLE 13. VALNEVA SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14. VIATRIS INC.: KEY EXECUTIVES
TABLE 15. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 16. VIATRIS INC.: OPERATING SEGMENTS
TABLE 17. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 18. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 19. ASTRAZENECA: KEY EXECUTIVES
TABLE 20. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 21. ASTRAZENECA: OPERATING SEGMENTS
TABLE 22. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 23. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24. EMERGEX VACCINES: KEY EXECUTIVES
TABLE 25. EMERGEX VACCINES: COMPANY SNAPSHOT
TABLE 26. EMERGEX VACCINES: OPERATING SEGMENTS
TABLE 27. EMERGEX VACCINES: PRODUCT PORTFOLIO
TABLE 28. EMERGEX VACCINES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 29. SANOFI: KEY EXECUTIVES
TABLE 30. SANOFI: COMPANY SNAPSHOT
TABLE 31. SANOFI: OPERATING SEGMENTS
TABLE 32. SANOFI: PRODUCT PORTFOLIO
TABLE 33. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34. BAVARIAN NORDIC A/S: KEY EXECUTIVES
TABLE 35. BAVARIAN NORDIC A/S: COMPANY SNAPSHOT
TABLE 36. BAVARIAN NORDIC A/S: OPERATING SEGMENTS
TABLE 37. BAVARIAN NORDIC A/S: PRODUCT PORTFOLIO
TABLE 38. BAVARIAN NORDIC A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 39. PROKARIUM: KEY EXECUTIVES
TABLE 40. PROKARIUM: COMPANY SNAPSHOT
TABLE 41. PROKARIUM: OPERATING SEGMENTS
TABLE 42. PROKARIUM: PRODUCT PORTFOLIO
TABLE 43. PROKARIUM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 45. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 46. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 47. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 48. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. GSK PLC.: KEY EXECUTIVES
TABLE 50. GSK PLC.: COMPANY SNAPSHOT
TABLE 51. GSK PLC.: OPERATING SEGMENTS
TABLE 52. GSK PLC.: PRODUCT PORTFOLIO
TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. UK VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF UK VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN UK VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: UK VACCINES MARKET
FIGURE 10. UK VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. UK VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 12. UK VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: UK VACCINES MARKET
FIGURE 19. TOP PLAYER POSITIONING,2023
FIGURE 20. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 21. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 22. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 23. VALNEVA SE: NET SALES, 2021-2023 ($BILLION)
FIGURE 24. VALNEVA SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. VALNEVA SE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 26. VIATRIS INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 27. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 29. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. EMERGEX VACCINES: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. EMERGEX VACCINES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. EMERGEX VACCINES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. BAVARIAN NORDIC A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. BAVARIAN NORDIC A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. BAVARIAN NORDIC A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. PROKARIUM: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. PROKARIUM: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. PROKARIUM: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. GSK PLC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)